GlassScriptPhysician profile
Eric J Brimhall
NPI 1134445109
$5,647.33
in general payments reported to CMS, 2019-2025
32 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $97.77 · 2021: $544 · 2022: $2,106 · 2023: $1,312 · 2024: $659 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463 · Education: $32.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.79 |
| Education | $32.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,687.58 | 2019-2024 | Proclaim, Eterna |
| Medtronic, INC. | $647.73 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $503.62 | 2019-2025 | General - Pain Management, Coveredge 32, General - Therapies |
| Scilex Pharmaceuticals INC. | $394.56 | 2019-2025 | Ztlido |
| Abbvie INC. | $345.26 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $290.52 | 2020-2025 | Belbuca, Xtampza, Nucynta |
| Nevro Corp. | $250.96 | 2019-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.50 | 2019-2024 | Relistor |
| Painteq LLC | $200.17 | 2021 | |
| Forte Bio-Pharma LLC | $166.59 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Spr Therapeutics, INC | $146.20 | 2022-2025 | Sprint Pns System |
| Lundbeck LLC | $129.67 | 2023-2025 | Vyepti |
| Vertos Medical, INC. | $119.83 | 2021 | |
| Globus Medical, INC. | $55.40 | 2025 | Omnia, Senza |
| Idorsia Pharmaceuticals US INC | $52.44 | 2022-2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $50.63 | 2019 | |
| Amgen INC. | $44.07 | 2022 | |
| Curonix LLC | $43.12 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Axsome Therapeutics, INC. | $41.59 | 2025 | Symbravo |
| Pfizer INC. | $33.97 | 2019 | |
| Biotronik Nro, INC. | $33.03 | 2024 | Prospera |
| Vertex Pharmaceuticals Incorporated | $25.60 | 2025 | |
| Vertiflex, INC. | $19.65 | 2019 | |
| Protega Pharmaceutials INC | $19.14 | 2024 | Roxybond |
| Fidia Pharma USA INC. | $16.98 | 2022 | |
| Biocomposites INC | $16.63 | 2025 | Stimulan |
| Lilly USA, LLC | $16.38 | 2023 | Emgality, Reyvow |
| Azurity Pharmaceuticals, INC. | $16.21 | 2023 | Horizant |
| Ibsa Pharma INC. | $15.70 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $13.41 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.26 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Brimhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.